Impact of Octreotide on Renal Function of Patients after Liver Transplantatio
- Conditions
- Z94.4iver Transplantation.Liver transplant status
- Registration Number
- IRCT20190619043942N1
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
1.Age between 18 and 60 years 2.Cirrhosis of the liver defined by clinical, biochemical or histological That, properly informed, give their consent to participate in the study and undergo tests and examinations that entails Women of childbearing potential: pregnancy test negative serum or urine, and acceptance of use of adequate contraception since at least 14 days prior to the first dose of study drug until 14 days after the last dose
1.Pregnant women, nursing mothers, or those who intend to become pregnant during the study period 2.Systolic blood pressure = 150 mmHg and / or diastolic blood pressure = 90 mmHg 3.Previous treatment with transjugular intrahepatic portosystemic shunt (TIPS) or surgical portosystemic shunts 4.Simultaneous Liver, Kidney Transplant 5.Cardiac or respiratory failure 6.Positive for human immunodeficiency virus 7.Urinary retention 8.Ischemic heart disease or peripheral vascular disease9.Narrow Angle Glaucoma 10.Cerebrovascular occlusions 11.Aortic Aneurysm 12.Thyrotoxicosis 13.Pheochromocytoma 14.Diabetes Melitus 15.History of Hemodialysis prior to Liver Transplant 16.PreTransplant Cr more than 2.5mg/dl
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Glomerular filtration. Timepoint: 3 Days after Intervention, 1week after Intervention, 4 weeks after Intervention. Method of measurement: Change in glomerular filtration rate measured by isotopic tests.
- Secondary Outcome Measures
Name Time Method Changes in renal function. Timepoint: 3days, 1 week, 4 weeks after cessation of treatment. Method of measurement: Lab test.